Contents
The Degradome and Its Analysis.- Protease Genomics and the Cancer Degradome.- The CLIP-CHIP™: A Focused Oligonucleotide Microarray Platform for Transcriptome Analysis of the Complete Human and Murine Cancer Degradomes.- The Hu/Mu ProtIn Chip: A Custom Dual-Species Oligonucleotide Microarray for Profiling Degradome Gene Expression in Tumors and Their Microenvironment.- Quantitative Real-Time PCR Analysis of Degradome Gene Expression.- Identification of Protease Substrates by Mass Spectrometry Approaches-1.- Identification of Protease Substrates by Mass Spectrometry Approaches-2.- Activity-Based Imaging and Biochemical Profiling Tools for Analysis of the Cancer Degradome.- Images of Cleavage: Tumor Proteases in Action.- Insights into Protease Function.- Proteolytic Pathways: Intersecting Cascades in Cancer Development.- Physiological Functions of Plasminogen Activation: Effects of Gene Deficiencies in Humans and Mice.- The Plasminogen Activation System in Tissue Remodeling and Cancer Invasion.- The Urokinase Plasminogen Activator Receptor as a Target for Cancer Therapy.- The Endocytic Collagen Receptor, uPARAP/Endo180, in Cancer Invasion and Tissue Remodeling.- Physiological and Pathological Functions of Type II Transmembrane Serine Proteases: Lessons from Transgenic Mouse Models and Human Disease-Associated Mutations.- Roles of Cysteine Proteases in Tumor Progression: Analysis of Cysteine Cathepsin Knockout Mice in Cancer Models.- In Vitro and In Vivo Models of Angiogenesis to Dissect MMP Functions.- The Surface Transplantation Model to Study the Tumor-Host Interface.- Unravelling the Roles of Proteinases in Cell Migration In Vitro and In Vivo.- New Insights into MMP function in Adipogenesis.- TIMPs: Extracellular Modifiers in Cancer Development.- The InterfaceBetween Proteolysis and Cell Signalling.- Invadopodia: Interface for Invasion.- uPAR and Proteases in Mobilization of Hematopoietic Stem Cells.- The Urokinase Receptor and Integrins Constitute a Cell Migration Signalosome.- Measuring uPAR Dynamics in Live Cells.- Janus-Faced Effects of Broad-Spectrum and Specific MMP Inhibition on Metastasis.- Cytokine Substrates: MMP Regulation of Inflammatory Signaling Molecules.- Matrix Metalloproteinases as Key Regulators of Tumor-Bone Interaction.- The Degradome as Source of Cancer Diagnostic and Markers.- The Plasminogen Activation System as a Source of Prognostic Markers in Cancer.- Cysteine Cathepsins and Cystatins as Cancer Biomarkers.- Novel Degradome Markers in Breast Cancer.- Meta-Analysis of Gene Expression Microarray Data: Degradome Genes in Healthy and Cancer Tissues.- Degradome Gene Polymorphisms.- TIMP-1 as a Prognostic Marker in Colorectal Cancer.- Novel Therapeutic Strategies.- Structure and Inhibition of the Urokinase-Type Plasminogen Activator Receptor.- Engineered Antagonists of uPA and PAI-1.- MMP Inhibitor Clinical Trials - The Past, Present, and Future.- Tailoring TIMPs for Selective Metalloproteinase Inhibition.- Third-Generation MMP Inhibitors: Recent Advances in the Development of Highly Selective Inhibitors.- Protease-Activated Delivery and Imaging Systems.- Development of Tumour-Selective and Endoprotease-Activated Anticancer Therapeutics.- Targeting Degradome Genes via Engineered Viral Vectors.
